Buzdin, Anton

Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death

Larkin, B., Ilyukha, V., Sorokin, M., Buzdin, A., Vannier, E., & Poltorak, A. (2017) · The Journal of Immunology

interferon and immune responsesImmune Response and Inflammation

Cited by 361

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 224

Spatial transcriptomics: Technologies, applications and experimental considerations

Wang, Y., Liu, B., Zhao, G., Lee, Y., Buzdin, A., Mu, X., Zhao, J., Chen, H., & Li, X. (2023) · Genomics

Single-cell and spatial transcriptomicsGene expression and cancer classification

Cited by 218

Pathway activation profiling reveals new insights into Age-related Macular Degeneration and provides avenues for therapeutic interventions

Makarev, E., Cantor, C., Zhavoronkov, A., Buzdin, A., Aliper, A., & Csoka, A. B. (2014) · Aging

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 50

Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways

Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 14